EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 38 / No 3 (September 2006) J Extra Corpor Technol, 38 3 (2006) 254-259 References
Free Access
Issue
J Extra Corpor Technol
Volume 38, Number 3, September 2006
Page(s) 254 - 259
DOI https://doi.org/10.1051/ject/200638254
Published online 15 September 2006
  1. Hedner U. Treatment of patients with VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost. 1999;82:531–9. [CrossRef] [PubMed] [Google Scholar]
  2. Midathada MV, Mehta P, Waner M, Fink LM. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol. 2004;121:124–37. [CrossRef] [PubMed] [Google Scholar]
  3. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VIIa for acute cerebral hemorrhage. N Engl J Med. 2005;352:777–85. [CrossRef] [PubMed] [Google Scholar]
  4. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998;9:119–28. [CrossRef] [PubMed] [Google Scholar]
  5. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion. 2002;42:114–24. [CrossRef] [PubMed] [Google Scholar]
  6. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia. 1999;5:253–9. [CrossRef] [PubMed] [Google Scholar]
  7. Jones LM, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9:464–520. [CrossRef] [PubMed] [Google Scholar]
  8. Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost. 2000;26:413–9. [Google Scholar]
  9. Key NS, Nelsestuen GL. Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol. 2004;41(Suppl 1):51–4. [CrossRef] [Google Scholar]
  10. Stammers AH, Trowbridge CC, Murdock JD, et al. The utility of the thromboelastograph during administration of rFVIIa in severely coagulopathic cardiac surgical patients. J Extra Corpor Technol. (in press). [Google Scholar]
  11. Trowbridge CC, Stammers AH, Brown B, et al. A novel transfusion algorithm for microvascular bleeding in cardiac surgery. J Extra Corpor Technol. (in press). [Google Scholar]
  12. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa—hemophilia and beyond. Semin Hematol. 2004;41(Suppl 1):140–4. [CrossRef] [Google Scholar]
  13. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol. 2004;41(Suppl 1):20–4. [CrossRef] [Google Scholar]
  14. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: A propensity score-matched case-control analysis. Transfusion. 2005;45:26–34. [CrossRef] [PubMed] [Google Scholar]
  15. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prosepective, randomized trial of two doses of rFVIIa in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–8. [CrossRef] [PubMed] [Google Scholar]
  16. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol. 1998;63(Suppl):7–10. [Google Scholar]
  17. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425–36. [Google Scholar]
  18. Lisman T, De Groot PHG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost. 2003;1:1138–9. [CrossRef] [Google Scholar]
  19. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993;92:1207–12. [CrossRef] [PubMed] [Google Scholar]
  20. Bjorquist P, Bostrom S. Determination of the kinetic constants of tissue factor/Factor VII/ Factor VIIa and antithrombin/heparin using surface plasmon resonance. Thromb Res. 1997;85:225–36. [CrossRef] [Google Scholar]
  21. Butena S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost. 2003;1:1158–60. [CrossRef] [Google Scholar]
  22. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175–9. [CrossRef] [PubMed] [Google Scholar]
  23. He S, Blomback M, Hedner U. Effect of rFVIIa on the permeability of fibrin gel. Blood. 2000;96:261a (abstract). [Google Scholar]
  24. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. 2002;99:923–30. [CrossRef] [PubMed] [Google Scholar]
  25. Teglt DS, Macik BG, McCord DM, et al. Mechanism by which recombinant factor VIIa shortens aPTT: Activation of factor X in the absence of tissue factor. Thromb Res. 1989;56:603–9. [CrossRef] [Google Scholar]
  26. Santagostino E, Morfini M, Rocino A, et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VII inhibitors. Thromb Haemost. 2001;86:954–8. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.